PepTalk 2017
PepTalk 2017
Archived Content

Antibodies for the 21st Century

Day 1 | Day 2 | Download Brochure


7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee



8:15 Chairperson's Remarks

Steffen Goletz, Ph.D., CEO, Glycotope GmbH

8:20 Novel Human Antibodies Targeting Mesothelin for Cancer Therapy

Mitchell HoMitchell Ho, Ph.D., Investigator and Head, Antibody Therapy Unit, Laboratory of Molecular Biology, National Cancer Institute, NIH - Biography

We discover and develop novel human monoclonal antibodies for cancer therapy. We study mesothelin as a potential therapeutic target. Along with our collaborators, we have established a tumor spheroid model cultured in vitro using established cancer cell lines and primary lines isolated from patients to explore novel approaches to antibody therapy with a focus on drug penetration.

8:50 Cell-Based Antibody Selection (CBAS™) Strategy for Generation of Fully Human Antagonistic Antibodies against GPCR Targets

Sergej KiprijanovSergej Kiprijanov, Ph.D., Vice President, Research & Pre-Clinical Development, Affitech Research AS - Biography

Using proprietary CBAS™ technology, Affitech generated a panel of antagonistic antibodies against GPCR targets involved in cancer progression and inflammation. The generated antibodies effectively competed with ligand binding, were able to block ligand-induced signaling and cell migration, and demonstrated high cell killing activity via ADCC. Data showing applicability of the GPCR targeting antibodies for treatment of cancer, inflammatory and autoimmune diseases will be presented.

9:20 Bertilimumab, a First-in-Class Fully Human Antibody Against Eotaxin-1 for the Treatment of Inflammatory Diseases

Daniel Teper, Ph.D., CEO, Immune Pharmaceuticals, Ltd.

Sponsored by
9:50 Structural Basis of a Protein Interaction Switch Regulating Stress-Dependent Transcription
Sean Crosson, Ph.D., Assistant Professor, Department of Biochemistry and Molecular Biology, The University of Chicago
Alphaproteobacteria integrate features of two-component signal transduction and alternative sigma regulation to control transcription in response to stress. We monitored changes in protein interaction under stress in this large diverse clade of bacteria

10:05 Coffee Break in the Exhibit Hall with Poster Awards



10:45 Isolation and Characterization of Therapeutic Antibody Charge Variants using Cation Exchange Displacement Chromatography

Tony Cano, Ph.D., Senior Engineer, Process Research and Development, Genentech, Inc. - Biography

We have demonstrated the isolation and enrichment of charge variants of a monoclonal antibody IgG1 using cation exchange displacement chromatography. We successfully achieved the separation of acidic, main and basic charge variants with high recovery (>70%) and purity (>90%) by using a commercially available stationary phase in conjunction with a commercially available displacer. Our results provide a case study demonstrating the utility of cation exchange displacement chromatography as a viable approach to isolate and enrich antibody charge variants for enhanced molecular characterization.

11:15 A Machine Learning Approach to Predict the Interface Angle in Antibodies

Abhinandan Raghavan, Ph.D., Senior Scientist, Section des Sciences Pharmaceutiques, University of Geneva

The talk will feature a novel method to predict the angle at the interface of the light and heavy chain variable region in an antibody from interface residues. This is an important factor to be considered in antibody engineering as the angle at the interface has a significant effect on the topography of the antigen-binding site. This work has significance in improved structural modelling of antibodies, as also in humanization protocols.

11:45 Epitope Mapping and Key Amino Acid Identification of Anti-CD22 Immunotoxin CAT-8015 using Hybrid β-Lactamase Display

David Bannister, Protein Sciences (Oncology), Lead Generation, Antibody Discovery & Protein Engineering, MedImmune

Determining the precise epitope of therapeutic antibodies is beneficial in understanding the structure–activity relationship of the drug, but in many cases is not done due to the structural complexity of, in particular, conformational protein epitopes. Using the immunotoxin CAT-8015 as a test case, this study demonstrates that a new methodology, hybrid β-lactamase display, can be employed to elucidate a complex epitope on CD22.

12:15 pm Close of Morning Session

12:30 Luncheon Presentations (Sponsorship Opportunity Available) or Lunch on Your Own

1:30 End of Conference

Day 1 | Day 2 | Download Brochure

Links to Companion Meetings

Pipeline 1

Bispecific Antibody Therapeutics

Recombinant Protein Therapeutics